3-Ethyl-1-methyl-9-piperidin-4-yl-1,3,9-triazaspiro[4.5]decane-2,4-dione | 923054-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-Ethyl-1-methyl-9-piperidin-4-yl-1,3,9-triazaspiro[4.5]decane-2,4-dione
• CAS: 923054-79-9
• 化学式: C₁₅H₂₆N₄O₂
• 分子量: 294.397
• InChiKey: GXTUTGDQGPEACA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  55.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Ethyl-1-methyl-9-piperidin-4-yl-1,3,9-triazaspiro[4.5]decane-2,4-dione 在 吡啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-ethyl-N'-(3-{[4-(3-ethyl-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.5]dec-7-yl)piperidin-1-yl]carbonyl}-1-benzothien-2-yl)urea
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors

  摘要：

  Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the spiro-lactone ring and the benzothiophene portion of the molecule. Spiro-imide derivative 8c containing a 6-methylthieno[2,3-b]pyridine core exhibited potent ACC inhibitory activity and favorable pharmacokinetic profiles in rats. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.047
• 作为产物：
  描述：

  2,4,4-二氧杂-1,3,7-三氮杂螺[4-]叔丁基-7-羧酸叔丁酯 在 盐酸 、 三乙酰氧基硼氢化钠 、 sodium hydride 、 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-Ethyl-1-methyl-9-piperidin-4-yl-1,3,9-triazaspiro[4.5]decane-2,4-dione
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors

  摘要：

  Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the spiro-lactone ring and the benzothiophene portion of the molecule. Spiro-imide derivative 8c containing a 6-methylthieno[2,3-b]pyridine core exhibited potent ACC inhibitory activity and favorable pharmacokinetic profiles in rats. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.047

文献信息

• SPIRO-CYCLIC COMPOUND
  申请人：Kamata Makoto

  公开号：US20100160255A1

  公开（公告）日：2010-06-24

  The present invention provides a compound represented by the formula (I): wherein E is an optionally substituted cyclic group; D is a carbonyl group or a sulfonyl group; A is CH or N; ring P is an optionally further substituted 5- to 7-membered ring; ring Q is an optionally further substituted 5- to 7-membered nonaromatic ring; and ring R is an optionally further substituted and optionally condensed 5- to 7-membered nonaromatic ring, or a salt thereof. The compound of the present invention has an ACC inhibitory activity, is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties in the efficacy, duration of activity, specificity, low toxicity and the like.

  本发明提供了一种由公式(I)表示的化合物：其中E是可选取代的环状基团；D是羰基基团或磺酰基团；A是CH或N；环P是可选取代的5-至7-成员环；环Q是可选取代的5-至7-成员非芳香环；环R是可选取代和可选缩合的5-至7-成员非芳香环，或其盐。本发明的化合物具有ACC抑制活性，对于预防或治疗肥胖症、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等疾病有用，并具有优越的疗效、活性持续时间、特异性、低毒性等特点。